Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer.

Cejas, Paloma; Xie, Yingtian; Font-Tello, Alba; Lim, Klothilda; Syamala, Sudeepa; Qiu, Xintao; Tewari, Alok K.; Shah, Neel; Nguyen, Holly M.; Patel, Radhika A.; Brown, Lisha; Coleman, Ilsa; Hackeng, Wenzel M.; Brosens, Lodewijk; Dreijerink, Koen M. A.; Ellis, Leigh; Alaiwi, Sarah Abou; Seo, Ji-Heui; Baca, Sylvan; Beltran, Himisha

Neuroendocrine carcinomas (NEC) are tumors expressing markers of neuronal differentiation that can arise at different anatomic sites but have strong histological and clinical similarities. Here we report the chromatin landscapes of a range of human NECs and show convergence to the activation of a common epigenetic program. With a particular focus on treatment emergent neuroendocrine prostate cancer (NEPC), we analyze cell lines, patient-derived xenograft (PDX) models and human clinical samples to show the existence of two distinct NEPC subtypes based on the expression of the neuronal transcription factors ASCL1 and NEUROD1. While in cell lines and PDX models these subtypes are mutually exclusive, single-cell analysis of human clinical samples exhibits a more complex tumor structure with subtypes coexisting as separate sub-populations within the same tumor. These tumor sub-populations differ genetically and epigenetically contributing to intra- and inter-tumoral heterogeneity in human metastases. Overall, our results provide a deeper understanding of the shared clinicopathological characteristics shown by NECs. Furthermore, the intratumoral heterogeneity of human NEPCs suggests the requirement of simultaneous targeting of coexisting tumor populations as a therapeutic strategy. Neuroendocrine carcinomas (NECs) arise from different anatomic sites, but have similar histological and clinical features. Here, the authors show that the epigenetic landscape of a range of NECs converges towards a common epigenetic state, while distinct subtypes occur within neuroendocrine prostate cancer contributing to intratumor heterogeneity in clinical samples.

PROSTATE cancer; EPIGENETICS; HETEROGENEITY; NEURONAL differentiation; TUMOR markers

Nature Communications, 2021, Vol 12, Issue 1, p1

2041-1723

Academic Journal

10.1038/s41467-021-26042-z